Is There a Role for Low-Dose Eltrombopag as Maintenance Therapy in the Treatment of Immune Thrombocytopenia?

Publisher： Karger

E-ISSN： 1421-9662|133|1|78-82

ISSN： 0001-5792

Source： Acta Haematologica, Vol.133, Iss.1, 2014-08, pp. : 78-82

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Effect of High-Dose Dexamethasone with or without Low-Dose Dexamethasone Maintenance in Untreated Immune Thrombocytopenia

By  

Acta Haematologica, Vol. 133, Iss. 1, 2014-09 ,pp. : 124-128

Karger

Access to resources Recommend Favorite

Use of eltrombopag after romiplostim in primary immune thrombocytopenia

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 1, 2015-04 ,pp. : 111-116

John Wiley & Sons Inc

Access to resources Recommend Favorite

Usage of Eltrombopag for Chronic Immune Thrombocytopenia as a Pretreatment for Splenectomy

By  

Acta Haematologica, Vol. 129, Iss. 1, 2012-10 ,pp. : 45-47

Karger

Access to resources Recommend Favorite

Combination therapy with bortezomib, continuous low‐dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 5, 2015-12 ,pp. : 720-725

John Wiley & Sons Inc

Access to resources Recommend Favorite

Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 3, 2015-03 ,pp. : E40-E43

John Wiley & Sons Inc

Access to resources Recommend Favorite